Skip to main content
In stock | Immunotherapy (Investigational)

Etentamig

Oncology Type Hematologic (Multiple Myeloma)
Drug Class / Mechanism Bispecific T-Cell Engager, BCMA x CD3
No Image
Description

Etentamig is classified as a Bispecific T-Cell Engager, BCMA x CD3, sourced for use within our Immunotherapy (Investigational) portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic Category Immunotherapy (Investigational)
Oncology Type Hematologic (Multiple Myeloma)

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3